6-K

- - --------------------------------------------------------------------------------

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549



                                    FORM 6-K

                            REPORT OF FOREIGN ISSUER

    PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934

                    FILING NO. 1 FOR THE MONTH OF JUNE, 2000




                              VISIBLE GENETICS INC.
                           --------------------------
                           (Exact name of Registrant)


             700 BAY STREET, SUITE 1000, TORONTO ON, CANADA M5G 1Z6
             ------------------------------------------------------
                    (Address of principal executive offices)



Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F

                    Form 20-F X               Form 40-F __

Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

                          Yes __           No X

- - --------------------------------------------------------------------------------








                              VISIBLE GENETICS INC.

         On June 28, 2000 Visible Genetics Inc. issued a press release
reporting on the status of its FDA submission for its TRUGENE HIV-1
Genotyping Kit.

         The press release is attached as Exhibit 1 to this Form 6-K and
incorporated into this Form 6-K by reference.

         This Form 6-K contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are subject to risks, uncertainties and
other factors which may cause our results to differ materially from
expectations. These include risks relating to the ability to obtain regulatory
approval, market acceptance of genotyping and our products and other risks
detailed from time to time in our SEC filings, including our most recent Annual
Report on Form 20-F. These forward-looking statements speak only as of the date
hereof. We disclaim any intent or obligation to update these forward-looking
statements.

         We hereby incorporate by reference this Form 6-K into our Registration
Statements on Form F-3, and into the prospectuses contained therein, (File Nos.
333-67607, 333-68939, 333-91155 and 333-94649) and our outstanding Registration
Statements on Form S-8 and into the reoffer prospectuses contained therein.

         Exhibit -- Press Release dated June 28, 2000







                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.



                                      VISIBLE GENETICS INC.


Date: June 28, 2000                   By: /s/ RICHARD T. DALY
                                         ---------------------------
                                         Name: Richard T. Daly
                                         Title: President and CEO

EX-99.1

                                                                    Exhibit 99.1

                      [LETTERHEAD OF VISIBLE GENETICS INC.]

                              For Immediate Release


Contacts:
Richard Daly (416) 813-3281             Bruno Maruzzo  (416) 813-3271
CEO, Visible Genetics Inc.              Investor Relations, Visible Genetics Inc


         VISIBLE GENETICS REPORTS ON TRUGENE HIV-1 GENOTYPING KIT STATUS



TORONTO, CANADA (June 28, 2000): Visible Genetics Inc. (VGI, Nasdaq: VGIN)
reported today on the status of the US FDA submission for its TRUGENE HIV-1
Genotyping Kit.

VGI has been working closely with the FDA to develop testing processes and trial
parameters appropriate for the TRUGENE HIV-1 Genotyping Kit, which we believe
would be the first ever sequencing-based diagnostic test submitted to the FDA
for approval. In 1999, in consultation with the FDA, the Company began
conducting a series of trials involving both human HIV plasma samples and
laboratory-constructed molecular infectious clones (MICs).

As of today, VGI has successfully completed and analyzed the results of the
performance and analytic trials, including all trials involving human HIV plasma
samples. The Company believes that the results of these tests confirm that the
TRUGENE HIV-1 Genotyping Kit functions as intended and at the level of
performance necessary to gain FDA clearance. VGI is currently performing one
final study involving laboratory-constructed MICs rather than samples drawn from
HIV infected patients. The Company has reviewed its progress to date with the
FDA and expects to complete the one remaining study in the coming weeks and
submit its application to the FDA in the third quarter of this year. The
remaining study using the MIC panels does not require additional clinical trials
or patient enrollment.

"I am very pleased with the performance of our TRUGENE HIV-1 Genotyping Kit on
the extensive set of clinical HIV samples studied in conjunction with preparing
our FDA submission," said Richard T. Daly, President and CEO of VGI. "While the
laboratory procedures associated with using MICs to







construct experimental HIV samples have taken slightly longer than initially
anticipated, we believe that the TRUGENE HIV-1 Genotyping Kit is on track to
become the first sequencing-based diagnostic test to be allowed for marketing in
the US."


Visible Genetics Inc. is a leader in the emerging field of pharmacogenomics,
which uses genetic information in the identification and analysis of genes to
improve patient care and reduce healthcare costs. VGI manufactures and markets
high performance automated DNA sequencing systems and complete kits for the
analysis of genes linked to disease. The Company's OpenGene(TM) system employs
patented CLIP(TM) technology - a single-step, bi-directional sequencing method
that significantly reduces the time and cost involved in identifying clinically
relevant genetic information.


This press release contains forward-looking statements within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform Act 1995.
These forward-looking statements are subject to risks and uncertainties and
other factors which may cause the Company's results to differ materially from
expectations. These include risks relating to the ability to obtain regulatory
approval, market acceptance of genotyping and the Company's products, and other
risks as detailed from time to time in the Company's SEC filings and most recent
Annual Report on Form 20-F. These forward-looking statements speak only as of
the date hereof. VGI disclaims any intent or obligation to update these
forward-looking statements.



                                       ###


                                       2